Stamakort
Research OnlyAlso known as: Gastric peptide, Stomach bioregulator, Gastric mucosa peptide
A peptide bioregulator developed by Russian scientist Vladimir Khavinson for gastric mucosa support. Claimed to modulate stomach lining gene expression and support digestive function. No Western clinical validation exists.
Research Statistics
Russian bioregulator (Khavinson lab); minimal published research even by Russian standards. Animal-only data from Russian Institute of Bioregulation. No human trials, no Western replication. Stomach tissue bioregulation mechanism is theoretical.
Research Dossier
Overview
What is Stamakort and what does the research say?
Mechanism of Action
Stamakort is proposed to support gastric mucosa through peptide bioregulation mechanisms developed by Vladimir Khavinson.
Proposed Mechanisms
- Mucosal Gene Modulation - Claimed to regulate gene expression in gastric mucosa cells
- Protective Function - Proposed effects on stomach lining integrity
- Digestive Support - Claimed involvement in gastric secretory function
Important Limitations
- No Western clinical validation or regulatory approval
- Limited Russian preclinical data only
- Amino acid sequence not fully characterized in public literature
- NOT a treatment for ulcers or gastric conditions
- No controlled human clinical trials
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
Peptide Interactions
Known and theoretical interactions when combining Stamakort with other peptides. Based on published research and mechanistic considerations.
Chonluten
CompatibleBoth target digestive system - Chonluten for GI tract broadly, Stamakort specifically for gastric mucosa.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Stamakort
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.